<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200831048570N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-07</date_registration>
      <primary_sponsor>Mohaghegh Ardabili University</primary_sponsor>
      <public_title>Effect of aerobic-yoga training and quinoa supplementation on serum Irisin, lipid profile and body mass index  overweight adult women</public_title>
      <acronym>AYQSILBW</acronym>
      <scientific_title>Evaluation the interactive effect of 8- week combined aerobic-yoga training and quinoa supplementation on serum Irisin levels, lipid profile and body mass index of overweight adult women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50622</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Overweight and obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Quinoa supplement group will consume cooked 25-gram quinoa  for 8 weeks and 3 days a week. (Quinoa seed is an organic products of Aman Quinoa in Hamedan). Intervention 2: Intervention group 2: 8-week combined aerobic-Yoga training,  three session per week, include twenty-minute yoga training and twenty-five minute aerobic exercise, fifteen- minute Recovery and yoga. Intervention 3: Intervention group 3: Exercise plus Supplement group will perform exercise program and use quinoa consumption simultaneously, like exercise group and supplement group. Intervention 4: Control group: No intervention was made.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After statistical analysis, the general information of the subjects will be shared in the form of final results and in the article, while preserving the privacy of the subjects and without identifying them.

When:
Access started from 1400

To whom:
Everyone

Conditions:
Everyone

Where to obtain:
n.ghayemalaei@student.uma.ac.ir

How to obtain:
Irandac tracking code

Comments:
The printer magazine is currently unknown</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nayyer Ghayyem Alaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mohaghegh Ardabili University.,University Street</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5619913131</zip>
        <telephone>+98 45 3326 0529</telephone>
        <email>n.ghayemalaei@student.uma.ac.ir</email>
        <affiliation>The Mohaghegh Ardabili University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nayyer ghayyem Alaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mohaghegh Ardabili University.,University Street</address>
        <city>Ardabil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5619913131</zip>
        <telephone>+98 45 3326 0529</telephone>
        <email>n.ghayemalaei@student.uma.ac.ir</email>
        <affiliation>The university of Mohaghegh</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range: 30-39 old years
Overweight women
Inactivity</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>39 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Absence of Anatomical, Orthopedic  and Physiological disease
No addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Quinoa supplement group will consume cooked 25-gram quinoa  for 8 weeks and 3 days a week. (Quinoa seed is an organic products of Aman Quinoa in Hamedan).</i_keyword>
      <i_keyword>Intervention group 2: 8-week combined aerobic-Yoga training,  three session per week, include twenty-minute yoga training and twenty-five minute aerobic exercise, fifteen- minute Recovery and yoga</i_keyword>
      <i_keyword>Intervention group 3: Exercise plus Supplement group will perform exercise program and use quinoa consumption simultaneously, like exercise group and supplement group.</i_keyword>
      <i_keyword>Control group: No intervention was made.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum levels of irisin. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the human ELISA kit of the German Zelbio company.</prim_outcome>
      <prim_outcome>High density lipoprotein. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoon company.</prim_outcome>
      <prim_outcome>Low density lipoprotein. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoon company.</prim_outcome>
      <prim_outcome>Very low density lipoprotein. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Using the formula triglyceride / 5.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoon company.</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoon company.</prim_outcome>
      <prim_outcome>Body mass indexe. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Weight (KG) / Square height (m).Weight measurement with German Beurer digital scale.Height measurement by calibrated wall with Chinese bar meter.</prim_outcome>
      <prim_outcome>Waist to hip ratio. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Waist measurement: In the narrowest part of the trunk, ie between the last rib and the crown of the iliac crest, a Chinese tape measure is completely attached to the skin and the size will be recorded without the skin being compressed.Measurement of hip circumference: Place a tape measure in the most voluminous part of the hip circumference, ie under the bulge of the pelvis, and the relevant number will be recorded without squeezing the skin.</prim_outcome>
      <prim_outcome>Percentage of body fat. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Using the three-point model (abdominal, scapular, triceps), Jackson and Pollack will perform a dynamic model caliper.First, the density will be obtained by the following formula: 2 (sum of three regions) 2 (0.00000084) + (sum of three regions) 000815 / 0-0982 / = body density.The percentage of fat will be obtained from the following formula: 450 - body density / 495 = body fat percentage.</prim_outcome>
      <prim_outcome>Lean body mass. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Body fat weight - total body weight = lean body mass.</prim_outcome>
      <prim_outcome>Body fat mass. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: body fat mass= (total weight×percentage of body fat ) / 100.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Serum levels of irisin. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the human ELISA kit of the German Zelbio company.</sec_outcome>
      <sec_outcome>Body mass indexe. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Weight (KG) / Square height (m).Weight measurement with German Beurer digital scale.Height measurement by calibrated wall with Chinese bar meter.</sec_outcome>
      <sec_outcome>Waist to hip ratio. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Waist measurement: In the narrowest part of the trunk, ie between the last rib and the crown of the iliac crest, a Chinese tape measure is completely attached to the skin and the size will be recorded without the skin being compressed.Measurement of hip circumference: Place a tape measure in the most voluminous part of the hip circumference, ie under the bulge of the pelvis, and the relevant number will be recorded without squeezing the skin.</sec_outcome>
      <sec_outcome>Percentage of body fat. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Using the three-point model (abdominal, scapular, triceps), Jackson and Pollack will perform a dynamic model caliper.First, the density will be obtained by the following formula: 2 (sum of three regions) 2 (0.00000084) + (sum of three regions) 000815 / 0-0982 / = body density.The percentage of fat will be obtained from the following formula: 450 - body density / 495 = body fat percentage.</sec_outcome>
      <sec_outcome>Lean body mass. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Body fat weight - total body weight = lean body mass.</sec_outcome>
      <sec_outcome>Body fat mass. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: body fat mass= (total weight×percentage of body fat ) / 100.</sec_outcome>
      <sec_outcome>High-density lipoprotein. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoun Company kit.</sec_outcome>
      <sec_outcome>Low density lipoprotein. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoun Company kit.</sec_outcome>
      <sec_outcome>Very low density lipoprotein. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Using the formula triglyceride / 5.</sec_outcome>
      <sec_outcome>Tri glyceride. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoun Company kit.</sec_outcome>
      <sec_outcome>Total cholesterol. Timepoint: 24 hours before the start of the study and 48 hours after the end. Method of measurement: Blood sampling in the amount of 5 cc and using the kit of Pars Azmoun Company kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mohaghegh Ardabili University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-26</approval_date>
        <contact_name>Ethics committee of Ardabil University of Medical Sciences</contact_name>
        <contact_address>Ardabil University of Medical Sciences., University Street, Ardabil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
